Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab dosing-duration safety study in thyroid eye disease
2024-515090-96-00Phase 4Completed
- Sponsor
- Horizon Therapeutics
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Teprotumumab with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, Treatment-emergent adverse events of special interest and 1 more. Started May 2022; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2024-515090-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515090-96-00.